Study of tuvusertib (M1774) in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors

This research study is focused on a new drug called tuvusertib, also known as M1774, for people living with certain types of advanced solid cancers. 'Solid cancers' are those that form a lump or tumour, like breast cancer, lung cancer, or bowel cancer, as opposed to blood cancers. When we say 'advanced', it means the cancer has either spread to other parts of the body (this is called metastatic cancer) or it's grown in a way that makes it impossible to remove with surgery locally.

The main goal of this study is to understand more about tuvusertib. It's a very early-stage study, sometimes called a Phase I study. This means the researchers are mainly looking at how the drug behaves in the human body – how it's absorbed, distributed, and removed. Importantly, they are also carefully checking for any side effects and trying to find the safest and most effective dose. Think of it like taking the first careful steps with a new medicine.

Another key part of this study is to see if tuvusertib can be given alongside other existing cancer treatments. Specifically, they are interested in combining it with drugs that target 'DNA damage response' – these are drugs that interfere with how cancer cells repair themselves, making them more vulnerable. They also want to see how it works with 'immune checkpoint inhibitors', which are medicines that help your own immune system recognise and attack cancer cells. By combining treatments, sometimes doctors can achieve better results than with one treatment alone, and this study aims to explore those possibilities.